FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 342:1539-1544 May 18, 2000 Number 20

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF Purchase this article Editorial by Angell, M. Letters Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

Clinical practice is changing rapidly. New cardiovascular drugs, antiinflammatory drugs, cancer chemotherapy, and other pharmacologic weapons are being added to physicians' therapeutic armamentarium virtually daily. Most clinical studies that bring new drugs from bench to bedside are financed by pharmaceutical companies. Many of these drug trials are rigorously designed, employing the skills of outstanding clinical researchers at leading academic institutions.

But academic medical centers are no longer the sole citadels of clinical research. The past 10 years have seen the spectacular growth of a new research model. Commercially oriented networks of contract-research organizations (CROs) and site-management organizations (SMOs) have altered . . . [Full Text of this Article]

The Clinical-Drug-Trial System

The Shift to Commercial Drug Networks

Industry–Investigator Relationships

Trial Design

Data Analysis

Publishing the Results

            Control over Publication

            Authorship

Conclusions

References

Related Letters:

Is Academic Medicine for Sale?
Ross L. F., Norton J. W., Young S. A., Lebowitz J., Leong G. B., Silva J. A., Dillon D. C., Jagger J., Firlik A. D., Lowry D. W., Diamond C., Ruane T. J., Hagan B. M., Miller P. D., Angell M.
Extract | Full Text  
N Engl J Med 2000; 343:508-510, Aug 17, 2000. Correspondence

Clinical Investigators and the Pharmaceutical Industry
Newman T. J., Bellin E., Bodenheimer T.
Extract | Full Text  
N Engl J Med 2000; 343:510-511, Aug 17, 2000. Correspondence

This article has been cited by other articles:

• Sade, R. M. (2009). Dangerous liaisons? Industry relations with health professionals.. J Law Med Ethics 37: 398-400  
• Fry-Revere, S., Malmstrom, D. B. (2009). More regulation of industry-supported biomedical research: are we asking the right questions?. J Law Med Ethics 37: 420-430  
• Gottlieb, S. (2009). Relationships with the drug industry: Build trust based on good science. BMJ 338: b234-b234 [Full Text]  
• Montgomery, K., Oliver, A. L. (2009). Shifts in guidelines for ethical scientific conduct: how public and private organizations create and change norms of research integrity.. Social Studies of Science 39: 137-155 [Abstract]  
• House, E. R. (2008). Blowback: Consequences of Evaluation for Evaluation. American Journal of Evaluation 29: 416-426 [Abstract]  
• Booth, C. M., Cescon, D. W., Wang, L., Tannock, I. F., Krzyzanowska, M. K. (2008). Evolution of the Randomized Controlled Trial in Oncology Over Three Decades. JCO 26: 5458-5464 [Abstract] [Full Text]  
• Buchanan, D., Sifunda, S., Naidoo, N., James, S., Reddy, P. (2008). Assuring Adequate Protections in International Health Research: A Principled Justification and Practical Recommendations for the Role of Community Oversight. Public Health Ethics 1: 246-257 [Abstract] [Full Text]  
• Perrin, R. S., Lopez, F. J G. (2008). Incremental Drug Treatment Cost in HIV-Positive Patients in Industry-Sponsored Clinical Trials. The Annals of Pharmacotherapy 42: 1586-1591 [Abstract] [Full Text]  
• Liesegang, T. J. (2008). Commercialism, Loss of Professionalism, and the Effect on Journals. Arch Ophthalmol 126: 1292-1295 [Full Text]  
• Hartley, H., Coleman, C.-L. (2008). News media coverage of direct-to-consumer pharmaceutical advertising: implications for countervailing powers theory. Health (London) 12: 107-132 [Abstract]  
• Campbell, E. G., Weissman, J. S., Ehringhaus, S., Rao, S. R., Moy, B., Feibelmann, S., Goold, S. D. (2007). Institutional Academic Industry Relationships. JAMA 298: 1779-1786 [Abstract] [Full Text]  
• Sernyak, M., Rosenheck, R. (2007). Experience of VA Psychiatrists With Pharmaceutical Detailing of Antipsychotic Medications. Psychiatr. Serv. 58: 1292-1296 [Abstract] [Full Text]  
• Iserson, K. V., Cerfolio, R. J., Sade, R. M. (2007). Politely Refuse the Pen and Note Pad: Gifts From Industry to Physicians Harm Patients. Ann. Thorac. Surg. 84: 1077-1084 [Full Text]  
• Parascandola, M. (2007). A Turning Point for Conflicts of Interest: The Controversy Over the National Academy of Sciences' First Conflicts of Interest Disclosure Policy. JCO 25: 3774-3779 [Abstract] [Full Text]  
• Gray, S. W., Hlubocky, F. J., Ratain, M. J., Daugherty, C. K. (2007). Attitudes Toward Research Participation and Investigator Conflicts of Interest Among Advanced Cancer Patients Participating in Early Phase Clinical Trials. JCO 25: 3488-3494 [Abstract] [Full Text]  
• Tungaraza, T., Poole, R. (2007). Influence of drug company authorship and sponsorship on drug trial outcomes. Br. J. Psychiatry 191: 82-83 [Abstract] [Full Text]  
• Friedman, J. Y, Sugarman, J., Dhillon, J. K, DePuy, V., Pierre, C. K, Dinan, M. A, Allsbrook, J. S, Schulman, K. A, Weinfurt, K. P (2007). Perspectives of clinical research coordinators on disclosing financial conflicts of interest to potential research participants. Clin Trials 4: 272-278 [Abstract]  
• Shea, A. M., DePuy, V., Allen, J. M., Weinfurt, K. P. (2007). Use and Perceptions of Clinical Practice Guidelines by Internal Medicine Physicians. American Journal of Medical Quality 22: 170-176 [Abstract]  
• Campbell, E. G., Gruen, R. L., Mountford, J., Miller, L. G., Cleary, P. D., Blumenthal, D. (2007). A National Survey of Physician-Industry Relationships. NEJM 356: 1742-1750 [Abstract] [Full Text]  
• Okike, K., Kocher, M. S. (2007). The Legal and Ethical Issues Surrounding Financial Conflict of Interest in Orthopaedic Research. JBJS 89: 910-913 [Full Text]  
• Okike, K., Kocher, M. S., Mehlman, C. T., Bhandari, M. (2007). Conflict of Interest in Orthopaedic Research. An Association Between Findings and Funding in Scientific Presentations. JBJS 89: 608-613 [Abstract] [Full Text]  
• Brody, H., Hunt, L. M. (2006). BiDil: Assessing a Race-Based Pharmaceutical. Ann Fam Med 4: 556-560 [Abstract] [Full Text]  
• Hilbrich, L., Sleight, P. (2006). Progress and problems for randomized clinical trials: from streptomycin to the era of megatrials. Eur Heart J 27: 2158-2164 [Abstract] [Full Text]  
• Grady, C., Horstmann, E., Sussman, J. S., Hull, S. C. (2006). The Limits of Disclosure: What Research Subjects Want to Know about Investigator Financial Interests. J Law Med Ethics 34: 592-599  
• Mintzberg, H. (2006). Patent nonsense: Evidence tells of an industry out of social control.. CMAJ 175: 374-374 [Full Text]  
• Hartley, H. (2006). The 'Pinking' of Viagra Culture: Drug Industry Efforts to Create and Repackage Sex Drugs for Women. Sexualities 9: 363-378 [Abstract]  
• McHenry, L (2006). Ethical issues in psychopharmacology.. J. Med. Ethics 32: 405-410 [Abstract] [Full Text]  
• Brown, S. D., Daly, J. C., Kalish, L. A., McDaniel, S. A. (2006). Financial Disclosures of Scientific Papers Presented at the 2003 RSNA Annual Meeting: Association with Reporting of Non-Food and Drug Administration-approved Uses of Industry Products. Radiology 239: 849-855 [Abstract] [Full Text]  
• Ridker, P. M, Torres, J. (2006). Reported outcomes in major cardiovascular clinical trials funded by for-profit and not-for-profit organizations: 2000-2005.. JAMA 295: 2270-2274 [Abstract] [Full Text]  
• Busfield, J. (2006). Pills, Power, People: Sociological Understandings of the Pharmaceutical Industry. Sociology 40: 297-314 [Abstract]  
• Tarrier, N. (2006). Negative Symptoms in Schizophrenia: Comments From a Clinical Psychology Perspective. Schizophr Bull 32: 231-233 [Abstract] [Full Text]  
• Heres, S., Davis, J., Maino, K., Jetzinger, E., Kissling, W., Leucht, S. (2006). Why Olanzapine Beats Risperidone, Risperidone Beats Quetiapine, and Quetiapine Beats Olanzapine: An Exploratory Analysis of Head-to-Head Comparison Studies of Second-Generation Antipsychotics. Am. J. Psychiatry 163: 185-194 [Abstract] [Full Text]  
• Henry, D., Doran, E., Kerridge, I., Hill, S., McNeill, P. M., Day, R. (2005). Ties That Bind: Multiple Relationships Between Clinical Researchers and the Pharmaceutical Industry. Arch Intern Med 165: 2493-2496 [Abstract] [Full Text]  
• Stossel, T. P. (2005). Regulating Academic-Industrial Research Relationships -- Solving Problems or Stifling Progress?. NEJM 353: 1060-1065 [Full Text]  
• Sierles, F. S., Brodkey, A. C., Cleary, L. M., McCurdy, F. A., Mintz, M., Frank, J., Lynn, D. J., Chao, J., Morgenstern, B. Z., Shore, W., Woodard, J. L. (2005). Medical Students' Exposure to and Attitudes About Drug Company Interactions: A National Survey. JAMA 294: 1034-1042 [Abstract] [Full Text]  
• Abramson, J., Starfield, B. (2005). The Effect of Conflict of Interest on Biomedical Research and Clinical Practice Guidelines: Can We Trust the Evidence in Evidence-Based Medicine?. J Am Board Fam Med 18: 414-418 [Full Text]  
• Genuis, S. J. (2005). The Proliferation of Clinical Practice Guidelines: Professional Development or Medicine-by-Numbers?. J Am Board Fam Med 18: 419-425 [Abstract] [Full Text]  
• Mirowski, P., Van Horn, R. (2005). The Contract Research Organization and the Commercialization of Scientific Research. Social Studies of Science 35: 503-548 [Abstract]  
• Hartling, L., McAlister, F. A., Rowe, B. H., Ezekowitz, J., Friesen, C., Klassen, T. P. (2005). Challenges in Systematic Reviews of Therapeutic Devices and Procedures. ANN INTERN MED 142: 1100-1111 [Abstract] [Full Text]  
• Mohl, P. C. (2005). Psychiatric Training Program Engagement With the Pharmaceutical Industry: An Educational Issue, Not Strictly an Ethical One. Acad. Psychiatry 29: 215-221 [Abstract] [Full Text]  
• Brodkey, A. C. (2005). The Role of the Pharmaceutical Industry in Teaching Psychopharmacology: A Growing Problem. Acad. Psychiatry 29: 222-229 [Abstract] [Full Text]  
• Spitz, B., Abramson, J. (2005). When Health Policy Is the Problem: A Report from the Field. Journal of Health Politics, Policy and Law 30: 327-366 [Abstract]  
• Mello, M. M., Clarridge, B. R., Studdert, D. M. (2005). Academic Medical Centers' Standards for Clinical-Trial Agreements with Industry. NEJM 352: 2202-2210 [Abstract] [Full Text]  
• Ryan, T. J., DeSanctis, R. W. (2005). Dr Jerome Kassirer's Book On The Take: How Medicine's Complicity With Big Business Can Endanger Your Health: Worthy of Comment. Circulation 111: 2552-2554 [Full Text]  
• Snyder, L., Leffler, C., for the Ethics and Human Rights Committee, America, (2005). Ethics Manual: Fifth Edition. ANN INTERN MED 142: 560-582 [Abstract] [Full Text]  
• Foladori, G. (2005). The Challenge of Infectious Diseases to the Biomedical Paradigm. Bulletin of Science Technology Society 25: 145-158 [Abstract]  
• Kavanaugh, A (2005). Ethical and practical issues in conducting clinical trials in psoriasis and psoriatic arthritis. Ann Rheum Dis 64: ii46-ii48 [Abstract] [Full Text]  
• Beecher, N., Harrison, E., Goldstein, N., McDaniel, M., Field, P., Susskind, L. (2005). Risk Perception, Risk Communication, and Stakeholder Involvement for Biosolids Management and Research. J. Environ. Qual. 34: 122-128 [Abstract] [Full Text]  
• Lexchin, J. R (2005). Implications of Pharmaceutical Industry Funding on Clinical Research. The Annals of Pharmacotherapy 39: 194-197 [Abstract] [Full Text]  
• King, T. E. Jr, Wheeler, M. B. (2004). Inequality in Health Care: Unjust, Inhumane, and Unattended!. ANN INTERN MED 141: 815-817 [Full Text]  
• Studdert, D. M., Mello, M. M., Brennan, T. A. (2004). Financial Conflicts of Interest in Physicians' Relationships with the Pharmaceutical Industry -- Self-Regulation in the Shadow of Federal Prosecution. NEJM 351: 1891-1900 [Full Text]  
• Freemantle, N., Stocken, D. (2004). The commercialization of clinical research: who pays the piper, calls the tune?. Fam Pract 21: 335-336 [Full Text]  
• Taekman, J. M., Hobbs, G., Barber, L., Phillips-Bute, B. G., Wright, M. C., Newman, M. F., Stafford-Smith, M. (2004). Preliminary Report on the Use of High-Fidelity Simulation in the Training of Study Coordinators Conducting a Clinical Research Protocol. Anesth. Analg. 99: 521-527 [Abstract] [Full Text]  
• Beal, K., Dean, J., Chen, J., Dragaon, E., Saulino, A., Collard, C. D. (2004). Budget Negotiation for Industry-Sponsored Clinical Trials. Anesth. Analg. 99: 173-176 [Abstract] [Full Text]  
• Helft, P. R., Ratain, M. J., Epstein, R. A., Siegler, M. (2004). Inside Information: Financial Conflicts of Interest for Research Subjects in Early Phase Clinical Trials. JNCI J Natl Cancer Inst 96: 656-661 [Abstract] [Full Text]  
• Buchkowsky, S. S, Jewesson, P. J (2004). Industry Sponsorship and Authorship of Clinical Trials Over 20 Years. The Annals of Pharmacotherapy 38: 579-585 [Abstract] [Full Text]  
• Schafer, A (2004). Biomedical conflicts of interest: a defence of the sequestration thesis--learning from the cases of Nancy Olivieri and David Healy. J. Med. Ethics 30: 8-24 [Abstract] [Full Text]  
• DuVal, G (2004). Institutional ethics review of clinical study agreements. J. Med. Ethics 30: 30-34 [Abstract] [Full Text]  
• Kim, S Y H, Millard, R W, Nisbet, P, Cox, C, Caine, E D (2004). Potential research participants' views regarding researcher and institutional financial conflicts of interest. J. Med. Ethics 30: 73-79 [Abstract] [Full Text]  
• Currie, C. (2003). Clinical arithmetic. BMJ 327: 1418-1419 [Full Text]  
• Kappos, L, Polman, C, Thompson, A J, Duda, P, Clanet, M, Comi, G, Hartung, H P, Montalban, X (2003). Towards a European Network for Multiple Sclerosis Trials (ENMST). Mult Scler 9: 627-629 [Abstract]  
• Bola, J. R. (2003). Integrity and bias in academic psychiatry. Br. J. Psychiatry 183: 464-464 [Full Text]  
• Bottomley, A., Efficace, F., Thomas, R., Vanvoorden, V., Ahmedzai, S. H. (2003). Health-Related Quality of Life in Non-Small-Cell Lung Cancer: Methodologic Issues in Randomized Controlled Trials. JCO 21: 2982-2992 [Abstract] [Full Text]  
• COOPER, B. (2003). Evidence-based mental health policy: a critical appraisal. Br. J. Psychiatry 183: 105-113 [Abstract] [Full Text]  
• Staropoli, J. F. (2003). Funding and Practice of Biomedical Research. JAMA 290: 112-112 [Full Text]  
• Chopra, S. S. (2003). Industry Funding of Clinical Trials: Benefit or Bias?. JAMA 290: 113-114 [Full Text]  
• Rosen, G. M., Davison, G. C. (2003). Psychology Should List Empirically Supported Principles of Change (ESPs) and Not Credential Trademarked Therapies or Other Treatment Packages. Behav Modif 27: 300-312 [Abstract]  
• LAGNADO, M. (2003). Increasing the trust in scientific authorship. Br. J. Psychiatry 183: 3-4 [Full Text]  
• Baird, P. (2003). Getting it right: industry sponsorship and medical research. CMAJ 168: 1267-1269 [Full Text]  
• Miller, F. G., Rosenstein, D. L. (2003). The Therapeutic Orientation to Clinical Trials. NEJM 348: 1383-1386 [Full Text]  
• Steinman, M. A., Gonzales, R., Linder, J. A., Landefeld, C. S. (2003). Changing Use of Antibiotics in Community-Based Outpatient Practice, 1991-1999. ANN INTERN MED 138: 525-533 [Abstract] [Full Text]  
• Bekelman, J. E., Li, Y., Gross, C. P. (2003). Scope and Impact of Financial Conflicts of Interest in Biomedical Research: A Systematic Review. JAMA 289: 454-465 [Abstract] [Full Text]  
• Schulman, K. A., Seils, D. M., Timbie, J. W., Sugarman, J., Dame, L. A., Weinfurt, K. P., Mark, D. B., Califf, R. M. (2002). A National Survey of Provisions in Clinical-Trial Agreements between Medical Schools and Industry Sponsors. NEJM 347: 1335-1341 [Abstract] [Full Text]  
• Relman, A. S., Bittl, J. A., Ferris, L. E., Korenman, S. K., Drazen, J. M., Curfman, G. D. (2002). Financial Associations of Authors. NEJM 347: 1043-1044 [Full Text]  
• Barnes, M., Florencio, P. S. (2002). Financial Conflicts of Interest in Human Subjects Research: The Problem of Institutional Conflicts. J Law Med Ethics 30: 390-402  
• Kennedy, H. L., Rosenson, R. S. (2002). Physicians' interpretation of "class effects": A need for thoughtful re-evaluation. J Am Coll Cardiol 40: 19-26 [Abstract] [Full Text]  
• (2002). The invisible hand of the marketing department. CMAJ 167: 5-5 [Full Text]  
• (2002). La main invisible du marketing. CMAJ 167: 7-7 [Full Text]  
• Caulfield, T., Griener, G. (2002). Conflicts of Interest in Clinical Research: Addressing the Issue of Physician Remuneration. J Law Med Ethics 30: 305-308  
• (2002). Scientific Data From Clinical Trials: Investigators' Responsibilities and Rights. Arch Surg 137: 639-640 [Full Text]  
• Zwart-van Rijkom, J.E.F., Broekmans, F.J., Leufkens, H.G.M. (2002). From HMG through purified urinary FSH preparations to recombinant FSH: a substitution study. Hum Reprod 17: 857-865 [Abstract] [Full Text]  
• Miller, F. G., Shorr, A. F. (2002). Ethical Assessment of Industry-Sponsored Clinical Trials* : A Case Analysis. Chest 121: 1337-1342 [Abstract] [Full Text]  
• Alpert, J. S., Furman, S., Smaha, L. (2002). Conflicts of Interest: Science, Money, and Health. Arch Intern Med 162: 635-637 [Full Text]  
• Lenzer, J., Warlow, C., Saver, J. L, Kidwell, C. S, Starkman, S. (2002). Alteplase for stroke: money and optimistic claims buttress the "brain attack" campaign * Commentary: Who pays the guideline writers? * Commentary: Thrombolysis in stroke: it works!. BMJ 324: 723-729 [Full Text]  
• Coyle, S. L., for the Ethics and Human Rights Committee, America, (2002). Physician-Industry Relations. Part 1: Individual Physicians. ANN INTERN MED 136: 396-402 [Abstract] [Full Text]  
• Nagy-Agren, S. (2002). The Crisis in Local Institutional Review Boards. ANN INTERN MED 136: 410-411 [Full Text]  
• Carpenter, W. T. Jr (2002). From Clinical Trial to Prescription. Arch Gen Psychiatry 59: 282-285 [Abstract] [Full Text]  
• Morin, K., Rakatansky, H., Riddick, F. A. Jr, Morse, L. J., O'Bannon III, J. M., Goldrich, M. S., Ray, P., Weiss, M., Sade, R. M., Spillman, M. A. (2002). Managing Conflicts of Interest in the Conduct of Clinical Trials. JAMA 287: 78-84 [Abstract] [Full Text]  
• Kalb, P. E., Koehler, K. G. (2002). Legal Issues in Scientific Research. JAMA 287: 85-91 [Abstract] [Full Text]  
• Anderson, J. (2001). The Francois Rabelais School of Medicine. BMJ 323: 1456-1457 [Full Text]  
• Abzug, M. J., Esterl, E. A. (2001). Establishment of a Clinical Trials Office at a Children's Hospital. Pediatrics 108: 1129-1134 [Abstract] [Full Text]  
• Vandenbroucke, J. P., de Craen, A. J.M. (2001). Alternative Medicine: A "Mirror Image" for Scientific Reasoning in Conventional Medicine. ANN INTERN MED 135: 507-513 [Abstract] [Full Text]  
• Fenster;, D. L., Winner, P. (2001). Migraine Treatment. Pediatrics 108: 817-817 [Abstract] [Full Text]  
• DeAngelis, C. D., Fontanarosa, P. B., Flanagin, A. (2001). Reporting Financial Conflicts of Interest and Relationships Between Investigators and Research Sponsors. JAMA 286: 89-91 [Full Text]  
• Jones, T. C (2001). Call for a new approach to the process of clinical trials and drug registration. BMJ 322: 920-923 [Full Text]  
• Drueke, T. B., Lameire, N. (2001). Report from the Editorial Office. Nephrol Dial Transplant 16: 29-31 [Full Text]  
• Lo, B., Wolf, L. E., Berkeley, A. (2000). Conflict-of-Interest Policies for Investigators in Clinical Trials. NEJM 343: 1616-1620 [Abstract] [Full Text]  
• McCrary, S. V., Anderson, C. B., Jakovljevic, J., Khan, T., McCullough, L. B., Wray, N. P., Brody, B. A. (2000). A National Survey of Policies on Disclosure of Conflicts of Interest in Biomedical Research. NEJM 343: 1621-1626 [Abstract] [Full Text]